Provided are a composition for preventing or treating diseases caused by immune dysfunction and metabolic dysfunction, including Lactobacillus bacteria-derived extracellular vesicles as an active ingredient, wherein, the Lactobacillus bacteria-derived vesicles may be distributed to major organs after being absorbed into the human body, and after being absorbed into cells, they may move to organelles to inhibit NF-κB signaling, which is a key signal of inflammatory responses, thereby regulating inflammatory responses; and the vesicles increase cell viability by activating AMPK signaling in metabolic stress situations where ATP production is poor, therefore it is expected that the vesicles may be effectively used in the development of pharmaceuticals or health functional foods for alleviating, preventing, or treating diseases caused by immune dysfunction or metabolic dysfunction.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61Q 19/08 - Préparations contre le vieillissement
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
2.
Method for diagnosis of lung disease based on antibodies for microbial-derived vesicles
The present invention relates to a method for diagnosing a lung disease based on antibodies against microorganism-derived vesicles and, more particularly, to a method for diagnosing a lung disease by performing bacterial metagenome analysis using samples derived from a subject to analyze an increase or decrease in IgG, IgG1 and/or IgG4 levels in extracellular vesicles derived from specific bacteria.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (République de Corée)
Inventeur(s)
Park, Hae-Sim
Choi, Youngwoo
Kim, Yoon-Keun
Abrégé
Provided is a method for providing information on chronic urticaria and, more specifically, the provided is a method for diagnosing chronic urticaria by measuring an allergen-specific IgE antibody for a vesicle derived from Acinetobacter bacteria; a diagnostic composition using the same; and the like.
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
4.
COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE, LIVER DISEASE, OR MUSCLE DISEASE COMPRISING LEUCONOSTOC SP. BACTERIA-DERIVED VESICLES
The present invention relates to a composition for preventing or treating a metabolic disease, a liver disease, or a muscle disease, the composition comprising Leuconostoc sp. bacteria-derived vesicles. The inventors of the present invention confirmed that, when Leuconostoc sp. bacteria-derived vesicles were administered to an animal model with a high-fat diet-induced metabolic disease, the vesicles efficiently suppressed the high-fat diet-induced metabolic disease, and when Leuconostoc sp. bacteria-derived vesicles were administered to an animal model with a liver disease induced by a choline-deficient, L-amino acid-defined high-fat diet, the vesicles efficiently suppressed the liver disease, and when Leuconostoc sp. bacteria-derived vesicles were administered to muscle cells, the vesicles increased AMPK signaling, which inhibits metabolic stress-induced cell death. Therefore, the Leuconostoc sp. bacteria-derived vesicles according to the present invention can be effectively used in the development of medicines, health functional foods or the like for preventing, ameliorating the symptoms of or treating a metabolic disease, a liver disease, a muscle disease, or the like.
A61K 35/744 - Bactéries lactiques, p. ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
5.
COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE, FIBROTIC DISEASE, OR MUSCLE DISEASE, COMPRISING LACTOBACILLUS SP. BACTERIA-DERIVED VESICLES
The present invention relates to a composition for prevention or treatment of metabolic disease, fibrotic disease, or muscle disease, comprising Lactobacillus sp. bacteria-derived vesicles. The inventors of the present invention have confirmed that when Lactobacillus sp. bacteria-derived vesicles are administered to an animal model for high-fat diet-induced metabolic disease, high-fat diet-induced metabolic disease is efficiently inhibited, and when Lactobacillus sp. bacteria-derived vesicles are administered to an animal model for choline-deficient L-amino acid-defined high-fat diet-induced non-alcoholic steatohepatitis and fibrotic disease, steatohepatitis and fibrotic disease are effectively inhibited, and when Lactobacillus acidophilus-derived vesicles are administered to muscle cells, the AMPK signals inhibiting metabolic stress-induced apoptosis increases, and thus the Lactobacillus sp. bacteria-derived vesicles according to the present invention may be usefully employed in the development of a medicinal product or a health functional food for prevention, symptom reduction, or treatment of metabolic disease, fibrotic disease, or muscle disease.
Provided are Lactobacillus acidophilus-derived vesicles and a use thereof, and more specifically, to a composition for alleviating, preventing, or treating an inflammatory disease and cancer, which includes Lactobacillus acidophilus-derived vesicles as an active ingredient.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61Q 19/00 - Préparations pour les soins de la peau
7.
LACTOBACILLUS PLANTARUM-DERIVED VESICLE AND USE THEREOF
Provided are Lactobacillus plantarum-derived vesicles and a use thereof and, more specifically, to a composition containing Lactobacillus plantarum-derived vesicles as an active ingredient for prevention, alleviation, or treatment of an immune disease or a metabolic disorder. Pathogenic factor-induced immune dysfunction and metabolite-induced metabolic dysfunction can be effectively inhibited when Lactobacillus plantarum-derive vesicles were administered into an immune disease or metabolic disorder model. Thus, the Lactobacillus plantarum-derived vesicles according to the presently claimed subject matter are expected to find advantageous applications in the development of medical products or health function foods for preventing or treating immune diseases or metabolic disorders or for alleviating symptoms thereof.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
8.
COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR CANCER, COMPRISING LEUCONOSTOC BACTERIA-DERIVED VESICLES
Provided is a method for alleviating, preventing, or treating inflammatory diseases or cancer by administering a composition including Leuconostoc bacteria-derived vesicles, which are able to effectively prevent or treat inflammatory diseases and cancer development and progression, as an active ingredient.
A61K 35/744 - Bactéries lactiques, p. ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Provided are a Lactobacillus rhamnosus-derived vesicle and uses thereof and a composition for preventing, alleviating, or treating immune diseases or cellular aging-related diseases, comprising the Lactobacillus rhamnosus-derived vesicle as an active ingredient, wherein the Lactobacillus rhamnosus-derived vesicle increases cellular homeostasis to suppress the occurrence of cellular aging-related diseases, and suppresses the occurrence of immune diseases by inhibiting immune hypersensitivity reactions in an immune disease model induced by viral causative factors, therefore the Lactobacillus rhamnosus-derived vesicle may be effectively used in the development of a drug or health functional food for preventing, alleviating, or treating viral infectious diseases, allergic immune diseases, autoimmune diseases, inflammatory diseases, cellular aging-related diseases, etc.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
10.
NANOVESICLES DERIVED FROM BACTERIA OF THE GENUS PARACOCCUS AND USE THEREOF
Provided are vesicles derived from bacteria of the genus Paracoccus and a use thereof in which the vesicles efficiently inhibit pathogenic biological factor-induced secretion of inflammatory mediators which induce inflammation, and the vesicles can be advantageously used for the purpose of preparing a composition for preventing, alleviating, or treating inflammatory diseases and be used therefor.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
11.
COMPOSITION FOR PREVENTION OR TREATMENT OF NEUTROPHILIC PULMONARY DISEASE COMPRISING EXTRACELLULAR VESICLES DERIVED FROM MICROCOCCUS LUTEUS
Provided is a method for ameliorating, preventing or treating neutrophilic pulmonary diseases, by administering a composition comprising Micrococcus luteus-derived vesicles as an active ingredient, the composition being capable of effectively treating a neutrophilic pulmonary disease mediated by a nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3 inflammasome (NLRP3 inflammasome).
A61K 35/744 - Bactéries lactiques, p. ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
Provided is Micrococcus luteus-derived extracellular vesicles and a use thereof and, more particularly, to a composition including Micrococcus luteus-derived extracellular vesicles as an active ingredient for alleviation, prevention, or treatment of metabolic diseases, wherein the composition can effectively treat metabolic diseases occurring as a result of a metabolism disorder, including: metabolic cardiovascular diseases such as metabolic syndrome, arteriosclerosis, stroke, and cardiac failure; metabolic liver diseases such as non-alcoholic steatohepatitis and hepatocirrhosis; metabolic renal diseases such as diabetic nephropathy, hypertensive nephropathy, and renal failure; and metabolic musculoskeletal disorders such as gout, sarcopenia, and osteoporosis.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
13.
COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISEASES OR PSYCHIATRIC DISEASES COMPRISING VESICLES DERIVED FROM SPHINGOMONAS BACTERIA
Provided is a use for preventing and treating neurological diseases or psychiatric diseases, including vesicles derived from Sphingomonas bacteria. The vesicles derived from Sphingomonas bacteria according to the presently claimed subject matter ameliorate symptoms caused by brain damage, such as memory ability and spatial perception ability, when administered to a brain disease mouse model, and therefore, are expected to be usefully used as a composition for preventing, alleviating or treating neurological diseases or psychiatric diseases.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
14.
COMPOSITION FOR PREVENTING, TREATING OR AMELIORATING EOSINOPHILIC INFLAMMATORY DISEASES OR TH2 HYPERSENSITIVITY IMMUNE DISEASES COMPRISING LACTOCOCCUS LACTIS-DERIVED VESICLES
Provided is a composition for preventing, treating or alleviating eosinophilic inflammatory diseases and Th2 hypersensitivity immune diseases, comprising Lactococcus lactis-derived vesicles, and it was confirmed that, when Lactococcus lactis-derived vesicles according to the presently claimed subject matter were administered to a Th2 hypersensitivity immune disease mouse model, the vesicles inhibited eosinophilic inflammation and the consequent functional and histopathological changes. It was also confirmed that the vesicles inhibited the secretion of Th2 cytokines such as IL-5 and IL-13 in T cells of the Th2 hypersensitivity immune disease mouse model, which is shown by inducing IL-12 secretion that suppresses a Th2 immune response in dendritic cells, which are antigen-presenting cells. Thus, the Lactococcus lactis-derived vesicles according to the presently claimed subject matter are expected to be effectively used in a composition and the like for preventing, treating or alleviating eosinophilic inflammatory diseases and Th2 hypersensitivity immune diseases.
The present invention relates to a method for preparing lactic acid bacterium-derived extracellular vesicles with improved yield. The inventors of the present invention have identified the optimal medium composition and fermentation conditions that can increase the yield of extracellular vesicles secreted by lactic acid bacteria. Specifically, there were problems with the conventional Lactobacillus culture medium, such as a small yield of extracellular vesicle, or inedible components of the medium, and toxicity due to animal-derived components. However, the present inventors have developed a medium that is not toxic, contains no animal-derived components, and is edible, and confirming that the medium is free of cytotoxicity and increases the yield of extracellular vesicles when culturing Lactobacillus. Furthermore, the present inventors identified the optimal culture time that can increase the yield. Therefore, the method of preparing extracellular vesicles with improved yield according to the present invention is expected to be beneficially used in processes for mass production on an industrial scale of extracellular vesicles secreted by lactic acid bacteria, which can be utilized as pharmacological components.
The present invention relates to vesicles derived from bacteria of the genus Collinsella and a use thereof. The inventors experimentally confirmed that the vesicles significantly decreased in a clinical sample obtained from a patient with gastric cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation, chronic obstructive pulmonary disease (COPD), diabetes, mild cognitive impairment or Alzheimer’s disease, compared with a normal person, and when the vesicles isolated from the strain were administered, the secretion of inflammation mediators caused by pathogenic vesicles such as E. coli-derived vesicles was considerably inhibited, and therefore, the vesicles derived from bacteria of the genus Collinsella according to the present invention may be effectively used to develop a method of diagnosing gastric cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation, COPD, diabetes, mild cognitive impairment or Alzheimer’s disease, and a composition for preventing, treating or alleviating the above-mentioned diseases or an inflammatory disease accompanying immune dysfunction.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Provided are a method for preventing, improving, or treating a neurological disorder, mental disorder, senescence, or symptoms thereof, comprising administering to a subject in need thereof vesicles derived from Lactobacillus paracasei as an active ingredient, and a pharmaceutical or functional food composition comprising the vesicles
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
18.
COMPOSITION FOR PREVENTING, TREATING, OR ALLEVIATING VIRAL INFECTION DISEASES OR RESPIRATORY DISEASES COMPRISING VESICLE DERIVED FROM LACTOBACILLUS PARACASEI
Provided is a method for preventing, alleviating, or treating a viral infectious disease or a respiratory disease, comprising administering a composition containing vesicles derived from Lactobacillus paracasei as an active ingredient to a subject in need thereof, wherein the vesicles may be orally administered and delivered to the lung to suppress a respiratory disease, administered to a COVID-19 virus- or influenza virus-infected model to suppress the replication of the COVID-19 virusand clinical symptoms caused by the influenza virus.
Sphingomonas are envisioned for use in methods of diagnosis, as well as compositions and methods for treating, hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis. These vesicles are also useful as drug carriers for drug delivery to the brain.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
20.
COMPOSITION FOR REGULATING STEM CELL FUNCTION COMPRISING THE GENUS LACTOBACILLUS BACTERIA-DERIVED EXTRACELLULAR VESICLES (EVS) AS AN ACTIVE INGREDIENT
CHUNGBUK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (République de Corée)
Inventeur(s)
Kim, Yoon-Keun
Park, Yoon Shin
Choi, Da Hyeon
Abrégé
Provided are a composition for regulating stem cell function comprising the genus Lactobacillus bacteria-derived extracellular vesicles as an active ingredient, and a method for regulating a stem cell function using the same, wherein the genus Lactobacillus bacterial-derived extracellular vesicles have the effect of greatly improving the proliferation of stem cells, and the extracellular vesicles are naturally secreted from a symbiotic the genus Lactobacillus strain in human tonsillar tissue and are human-friendly and natural substances, and thus can be used in various research fields by promoting the proliferation of aged stem cells with minimal toxicity and side effects.
The present invention relates to a method of diagnosing depression through bacterial metagenomic analysis, and more particularly to a method of diagnosing depression by analyzing an increase or decrease in content of specific bacteria-derived extracellular vesicles through bacterial metagenomic analysis using subject-derived samples, and the like. Extracellular vesicles secreted from microorganisms such as bacteria and archaea, present in the environment, are absorbed into the body and thus can directly affect the occurrence of inflammation, and depression characterized by an inflammatory response is difficult to diagnose early before symptoms appear so that effective treatment is difficult. Therefore, by previous diagnosis of the risk for the onset of depression through metagenomic analysis of bacteria-derived extracellular vesicles using human-derived samples according to the present invention, the risk group of depression can be diagnosed and predicted early to delay or prevent the onset of depression through proper management, and early diagnosis can be performed even after the onset, thereby reducing the incidence of depression and increasing the therapeutic effect.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
22.
NANOVESICLES DERIVED FROM COPROCOCCUS SP. BACTERIA, AND USE THEREOF
The present invention relates to vesicles derived from bacteria of the genus Coprococcus and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in clinical samples obtained from patients with breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy and atrial fibrillation, compared with a normal individual, and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited. Therefore, it is expected that the vesicles derived from bacteria of the genus Coprococcus according to the present invention can be effectively used for a method of diagnosing breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy or atrial fibrillation, and for developing a composition for preventing, treating or alleviating gastritis, gastric cancer, colitis, colon cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation or an inflammatory disease.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
23.
METHOD FOR DIAGNOSING AUTISM BY ANALYZING BACTERIAL METAGENOME
Provided are a method of diagnosing autism by performing a bacterial metagenomic analysis using normal individual-derived and subject-derived samples to analyze an increase or decrease in the content of specific bacteria-derived extracellular vesicles. The method predicts the risk of autism onset in advance through the metagenomic analysis of bacteria-derived extracellular vesicles using human body-derived samples, and it is possible to delay the onset time or prevent the onset of autism through proper management following early diagnosis and prediction of an autism risk group, and even after the onset, it is possible to diagnose autism early, thereby lowering the incidence of autism and increasing therapeutic effects.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
24.
COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR CANCER, COMPRISING LEUCONOSTOC BACTERIA-DERIVED VESICLES
The present invention relates to Leuconostoc bacteria-derived vesicles and a use thereof, and more specifically, to a composition for alleviating, preventing, and treating inflammatory diseases or cancer, comprising, as an active ingredient, Leuconostoc bacteria-derived vesicles capable of effectively preventing and treating the occurrence and progress of inflammatory diseases or cancer.
A61K 35/744 - Bactéries lactiques, p. ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to Lactobacillus plantarum-derived vesicles and a use thereof and, more specifically, to a composition containing Lactobacillus plantarum-derived vesicles as an active ingredient for prevention, alleviation, or treatment of an immune disease or a metabolic disorder. The present inventors found that when Lactobacillus plantarum-derived vesicles were administered into an immune disease or metabolic disorder model, pathogenic factor-induced immune dysfunction and metabolite-induced metabolic dysfunction can be effectively inhibited. Thus, the Lactobacillus plantarum-derived vesicles according to the present invention are expected to find advantageous applications in the development of medical products or health function foods for preventing or treating immune diseases or metabolic disorders or for alleviating symptoms thereof.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61Q 19/00 - Préparations pour les soins de la peau
26.
LACTOBACILLUS ACIDOPHILUS-DERIVED VESICLE AND USE THEREOF
The present invention relates to Lactobacillus acidophilus-derived vesicles and a use thereof and, more specifically, to a composition containing Lactobacillus acidophilus-derived vesicles as an active ingredient for alleviating, preventing, and treating inflammatory diseases and cancer.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61Q 19/00 - Préparations pour les soins de la peau
27.
LACTOBACILLUS RHAMNOSUS-DERIVED VESICLE AND USES THEREOF
The present invention relates to a Lactobacillus rhamnosus-derived vesicle and uses thereof, and to a composition for preventing, alleviating, or treating immune diseases or cellular senescence-related diseases comprising a Lactobacillus rhamnosus-derived vesicle as an active ingredient. The present inventors have confirmed that a Lactobacillus rhamnosus-derived vesicle increases cellular homeostasis to suppress the occurrence of cellular senescence-related diseases, and suppresses the occurrence of immune diseases by inhibiting immune hypersensitivity reactions in an immune disease model caused by viral causative factors. Accordingly, the Lactobacillus rhamnosus-derived vesicle according to the present invention may be effectively used in the development of a drug or health functional food for preventing, alleviating, or treating viral infectious diseases, allergic immune diseases, autoimmune diseases, inflammatory diseases, cellular senescence-related diseases, etc.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61Q 19/00 - Préparations pour les soins de la peau
28.
EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS BACTERIA, AND USE THEREOF
The present invention relates to a composition for preventing or treating diseases caused by immune and metabolic disorders, comprising, as an active ingredient, extracellular vesicles derived from Lactobacillus bacteria. The vesicles derived from Lactobacillus bacteria, according to the present invention, spread to major organs after being absorbed into the body, move to organelles after being absorbed into cells, and then inhibit NF-κB signaling, which are crucial signals of the inflammatory response and thus can regulate same. In addition, vesicles according to the present invention activate AMPK signals under metabolic stress conditions during which ATP production is inhibited and increases the viability of cells under metabolic stress conditions, and thus are expected to be effectively used in the development of medicine, or functional food for health, and the like for alleviating, preventing, or treating diseases caused by immune and metabolic disorders.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61Q 19/00 - Préparations pour les soins de la peau
29.
COMPOSITION FOR PREVENTING OR TREATING EYE DISEASES COMPRISING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS PARACASEI
The present invention relates to extracellular vesicles derived from Lactobacillus paracasei and use thereof and, more specifically, to a composition for ameliorating, preventing and treating eye diseases, comprising, as an active ingredient, Lactobacillus paracasei-derived vesicles that can effectively suppress the occurrence of eye diseases, which occur in relation to cellular senescence caused by oxidative stress.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61Q 19/00 - Préparations pour les soins de la peau
30.
NANOVESICLES DERIVED FROM PARACOCCUS SP. BACTERIA AND USE THEREOF
The present invention relates to Paracoccus sp. bacterium-derived vesicles and a use thereof. The present inventors have experimentally confirmed that Paracoccus sp. bacterium-derived vesicles efficiently inhibit pathogenic biological factor-induced secretion of inflammatory mediators which induce inflammation, and it is thus expected that the Paracoccus sp. bacterium-derived vesicles according to the present invention can be advantageously used for the purpose of developing a composition for preventing, alleviating, or treating inflammatory diseases.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61Q 19/00 - Préparations pour les soins de la peau
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
31.
Inflammatory bowel disease diagnostic method by means of bacterial metagenomic analysis
The present invention relates to a method for prognosing the occurrence and the causative factor of an inflammatory bowel disease such as ulcerative colitis and Crohn's disease by means of a metagenomic analysis of bacterial and bacterial-derived vesicles present in a human body-derived substance and, more particularly, to a method for diagnosing the causative factor and occurrence risk of an inflammatory bowel disease by analyzing a metagenomic sequence present in bacteria and bacteria-derived vesicles present in stool. Trillions of bacteria are present in the intestine, and vesicles are secreted outside the cells for exchange of information. Bacterial are not absorbed into the intestinal epithelial cells, but the vesicles secreted from the bacteria pass through the mucous, are absorbed into the intestinal epithelial cells and can increase or reduce inflammation. The present invention can be facilitated as a method for diagnosing the occurrence risk and causative factor of an inflammatory bowel disease by means of a gene metagenomic sequence analysis of bacteria and bacterial=-derived vesicles present in a human body-derived substance. Also, the present invention enables early diagnosis even after an occurrence of an inflammatory bowel disease, reduces the occurrence of an inflammatory bowel disease, and can enhance therapeutic effects.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
32.
METHOD FOR DIAGNOSING BRAIN TUMOR THROUGH BACTERIAL METAGENOMIC ANALYSIS
SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (République de Corée)
Inventeur(s)
Kim, Yoon-Keun
Paek, Sun Ha
Moon, Hyo Eun
Park, Hyung Woo
Abrégé
Provided is a method of diagnosing a brain tumor by analyzing the increase or decrease in content of specific bacteria-derived extracellular vesicles by performing bacterial metagenomic analysis using a normal individual and a subject-derived sample, which makes it possible to diagnose and predict a risk group for a brain tumor early, to delay or prevent the onset of the disease through appropriate management, and even after the onset of a brain tumor, early diagnosis can be performed to reduce the incidence of the brain tumor, a therapeutic effect cannot be only increased, and the disease can be improved and recurrence thereof can be prevented by avoiding exposure to causative factors through metagenomic analysis in patients diagnosed with a brain tumor.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
33.
Method for diagnosing prostatic disease via bacterial metagenomic analysis
A method of diagnosing prostatic diseases such as prostate cancer, prostatic hyperplasia, and the like through bacterial metagenomic analysis, and more particularly, to a method of diagnosing prostate cancer or prostatic hyperplasia by analyzing an increase or decrease in content of extracellular vesicles derived from specific bacteria through bacterial metagenomic analysis using a subject-derived sample. An extracellular vesicle secreted from a bacterium present in the environment can be absorbed into the body and directly affect the occurrence of inflammation and cancer, and prostatic diseases such as prostate cancer, prostatic hyperplasia, and the like is difficult to diagnose early on before any symptom appears, which makes efficient treatment difficult. As such, through the metagenomic analysis on a gene present in a bacterium-derived extracellular vesicle using a human body-derived sample according to the present invention, the risk of the onset of prostate cancer and prostatic hyperplasia can be predicted in advance.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC DISORDERS OR MUSCULAR DISEASES COMPRISING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS BACTERIA
Provided is a composition for preventing or treating a metabolic disease or muscle disease, which includes vesicles derived from bacteria of the genus Lactobacillus. Confirmed, when vesicles derived from bacteria of the genus Lactobacillus were administered into an animal model with a metabolic disease caused by a high fat, the vesicles effectively inhibit metabolic diseases caused by a high fat diet, and increase homeostasis to metabolic stress by activating AMPK signaling in myocytes, and therefore, the vesicles derived from bacteria of the genus Lactobacillus according to the presently claimed subject matter can be effectively used in development of pharmaceuticals or health functional foods for preventing, improving symptoms or treating metabolic diseases such as obesity and muscle diseases.
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
35.
METHOD FOR DIAGNOSIS OF COLITIS THROUGH QPCR ANALYSIS
Provided is a method of diagnosing colitis through qPCR analysis and to a method of diagnosing colitis by measuring amounts of microorganisms in stool samples to be analyzed. The diagnosis method according to the presently claimed subject matter can predict and/or diagnose colitis at high accuracy and sensitivity by using stool, which can be easily acquired without pain from a subject to be diagnosed, and as such, can find a wide range of applications in the colitis diagnosis field and, as a result, is expected to enable early diagnosis of colitis, thereby remarkably increasing the effects of colitis treatment.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
Lactobacillus paracasei as an active ingredient to a subject in need thereof, wherein the vesicles may be orally administered and delivered to the lung to suppress a respiratory disease, administered to a COVID-19 virus- or influenza virus-infected model to suppress the replication of the COVID-19 virus and clinical symptoms caused by the influenza virus.
COMPOSITION INCLUDING LACTOBACILLUS PARACASEI-DERIVED VESICLES FOR PREVENTING, TREATING, OR ALLEVIATING VIRAL INFECTIOUS DISEASES OR RESPIRATORY DISEASES
The present invention relates to a composition including Lactobacillus paracasei-derived vesicles as an active ingredient for preventing, alleviating, or treating viral infectious diseases or respiratory diseases. The present inventors have confirmed that when vesicles are isolated from Lactobacillus paracasei bacteria and administered orally, the vesicles are delivered to the lungs, and the occurrence of respiratory diseases is significantly inhibited when the vesicles are administered to an animal model for respiratory diseases caused by chemical, viral, and bacterial causative factors. In addition, it was confirmed that when Lactobacillus paracasei-derived vesicles are administered to a COVID-19 virus or influenza virus infection model, replication of the COVID-19 virus is remarkably inhibited, the occurrence of pneumonia is significantly inhibited, and clinical symptoms caused by the influenza virus are significantly inhibited. Therefore, the Lactobacillus paracasei-derived vesicles according to the present invention are expected to be useful for developing medicines or functional health foods for preventing, alleviating symptoms of, or treating viral infectious diseases or respiratory diseases.
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
38.
COMPOSITION FOR PREVENTION OR TREATMENT OF NEUTROPHILIC PULMONARY DISEASE COMPRISING EXTRACELLULAR VESICLES DERIVED FROM MICROCOCCUS LUTEUS
The present invention relates to extracellular vesicles derived from Micrococcus luteus and use thereof and, in particular, to a composition and the like for ameliorating, preventing or treating neutrophilic pulmonary disease, comprising vesicles derived from Micrococcus luteus, as an active ingredient, the composition being capable of effectively treating neutrophilic pulmonary disease mediated by a nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3 inflammasome (NLRP3 inflammasome).
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
39.
COMPOSITION FOR PREVENTING OR TREATING NEURODEVELOPMENTAL, NEUROLOGICAL OR PSYCHIATRIC DISEASES, COMPRISING EXTRACELLULAR VESICLES DERIVED FROM MICROCOCCUS LUTEUS
The present invention relates to extracellular vesicles derived from Micrococcus luteus, and a use thereof and, more specifically, to a composition and the like for alleviating, preventing, or treating neurodevelopmental, neurological or psychiatric diseases, comprising, as an active ingredient, Micrococcus-luteus-derived vesicles, which can effectively treat diseases, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, diabetic neuropathy, autism spectrum disorder, attention deficit hyperactivity disorder, a depressive disorder, bipolar mood disorder, an anxiety disorder, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, a dissociative disorder, an eating disorder, a substance use disorder, and a personality disorder, which result from impaired neurogenesis or neuroinflammation.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to a composition for preventing, ameliorating, or treating eye diseases, the composition containing Micrococcus luteus-derived vesicles as an active ingredient. The present inventors have confirmed that when the vesicles are administered orally, the vesicles pass through the blood-brain barrier (BBB) and are thereby delivered to the central nervous system including the retina. In addition, not only was treating epithelial cells and macrophages with the vesicles found to remarkably inhibit the secretion of inflammatory mediators by biological causal factors, but treating cells with the vesicles was found to inhibit the expression of NLRP3 protein by biological causal factors. Furthermore, administering the vesicles to rabbit models with eye diseases caused by oxidative stress was found to significantly suppress the onset of retinal degeneration caused by oxidative stress. Therefore, the Micrococcus luteus-derived vesicles according to the present invention can be used as a composition for preventing, ameliorating, or treating aging-related eye diseases and inflammatory eye diseases, and can also be useful for the development of medicines or functional health foods for preventing, ameliorating, or treating aging-related eye diseases and inflammatory eye diseases.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to Micrococcus luteus-derived extracellular vesicles and use thereof and, more specifically, a composition comprising Micrococcus luteus-derived extracellular vesicles as an active ingredient for alleviation, prevention, or treatment of metabolic diseases, wherein the composition can effectively treat metabolic diseases occurring as a result of disturbance of metabolism, including: metabolic cardiovascular diseases such as metabolic syndrome, arteriosclerosis, stroke, cardiac failure, etc.; metabolic liver diseases such as non-alcoholic steatohepatitis, hepatocirrhosis, etc.; metabolic renal diseases such as diabetic nephropathy, hypertensive nephropathy, renal failure, etc.; and metabolic musculoskeletal disorders such as gout, sarcopenia, osteoporosis, etc.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Micrococcus luteus can be used for a composition for preventing, alleviating or treating an age-related ocular disease and an inflammatory ocular disease, including a pharmaceutical or health functional food composition.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
44.
Composition for prevention or treatment of ocular diseases comprising extracellular vesicles derived from lactobacillus paracasei
Lactobacillus paracasei-derived extracellular vesicles as an active ingredient, capable of effectively inhibiting the occurrence of an ocular disease caused by oxidative stress-mediated cell senescence.
The present invention relates to use for preventing and treating neurological diseases or psychiatric diseases, comprising vesicles derived from Sphingomonas bacteria. The inventors of the present invention confirmed that, when vesicles were isolated from a culture medium of the bacteria and orally administered, the vesicles were delivered into the brain, and, when the vesicles were administered to a brain disease animal model, not only was neurogenesis increased but also the connectivity between neurons was increased, and also confirmed that such therapeutic effects were induced by increasing the expression of neurotrophic factors and receptor genes and simultaneously increasing the expression of Sirt1, Sirt5, and Sirt7 genes that inhibit cellular senescence. In addition, it has been confirmed that vesicles derived from Sphingomonas bacteria inhibit the secretion of inflammatory mediators from inflammatory cells caused by neurological diseases or pathogenic factors. Thus, the vesicles derived from Sphingomonas bacteria according to the present invention improve symptoms caused by brain damage, such as memory ability and spatial perception ability, when administered to a brain disease mouse model, and therefore, are expected to be effectively used in a composition for preventing, ameliorating or treating neurological diseases or psychiatric diseases.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
46.
Nano-vesicle derived from catenibacterium bacteria and use thereof
Catenibacterium according to the present invention can be effectively used for a method of diagnosing a malignant disease such as colon cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer or lymphoma, a cardiovascular disease such as myocardial infarction, atrial fibrillation, variant angina pectoris or stroke, diabetes, Parkinson's disease, and depression, and for developing a composition for preventing or treating the diseases.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (République de Corée)
Inventeur(s)
Park, Hae-Sim
Choi, Youngwoo
Kim, Yoon-Keun
Abrégé
The present invention relates to a method for providing information about chronic urticarial and, more specifically, to: a method for diagnosing chronic urticarial by measuring an allergen-specific IgE antibody for a vesicle derived from acinetobacter bacteria; a diagnostic composition using same; and the like.
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
48.
COMPOSITION FOR PREVENTING, TREATING OR AMELIORATING EOSINOPHILIC INFLAMMATORY DISEASES OR TH2 HYPERSENSITIVITY IMMUNE DISEASES COMPRISING LACTOCOCCUS LACTIS-DERIVED VESICLES
The present invention relates to a composition for preventing, treating or ameliorating eosinophilic inflammatory diseases or Th2 hypersensitivity immune diseases, comprising Lactococcus lactis-derived vesicles, and it was confirmed that, when Lactococcus lactis-derived vesicles according to the present invention were administered to a Th2 hypersensitivity immune disease mouse model, the vesicles inhibited eosinophilic inflammation and the consequent functional and histopathological changes. It was also confirmed that the vesicles inhibited the secretion of Th2 cytokines such as IL-5 and IL-13 in T cells of the Th2 hypersensitivity immune disease mouse model, which is shown by inducing IL-12 secretion that suppresses a Th2 immune response in dendritic cells, which are antigen-presenting cells. Thus, the Lactococcus lactis-derived vesicles according to the present invention are expected to be effectively used in a composition and the like for preventing, treating or ameliorating eosinophilic inflammatory diseases and Th2 hypersensitivity immune diseases.
Provided is a method of diagnosing diabetes, atrial fibrillation, cardiomyopathy, liver cancer, cirrhosis, dementia, depression, Parkinson's disease, or atopic dermatitis, including (a) extracting DNAs from vesicles isolated from samples of a normal individual and a subject; (b) performing PCR (Polymerase Chain Reaction) on the extracted DNA using a pair of primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and (c) determining a case in which a content of vesicles derived from bacteria of the genus Rothia is lower than that of the normal individual sample, as one or more diseases selected from the group consisting of diabetes, atrial fibrillation, cardiomyopathy, liver cancer, cirrhosis, dementia, depression, Parkinson's disease, and atopic dermatitis, through quantitative analysis of the PCR product.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Provided are vesicles derived from bacteria of the genus Deinococcus and a use thereof. The vesicles significantly decreased in a clinical sample obtained from a patient with cancer, an inflammatory disease, and dementia, compared with a normal individual, and when the vesicles isolated from the strain were administered, the secretion of inflammation mediators caused by pathogenic vesicles such as E. coli-derived vesicles was considerably inhibited, and vesicles derived from bacteria of the genus Deinococcus significantly inhibit cranial nerve cell damage caused by stress hormones, and therefore, the vesicles derived from bacteria of the genus Deinococcus according to the presently claimed subject matter may be effectively used to develop a method of diagnosing cancer, an inflammatory disease, and/or dementia, and a composition for preventing, alleviating, or treating cancer, an inflammatory disease, and/or a cranial nerve disease.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61Q 19/00 - Préparations pour les soins de la peau
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
52.
NANOVESICLES DERIVED FROM BACTERIA OF GENUS RHODOCOCCUS, AND USE THEREOF
Provided is a method of diagnosing or treating a disease in a subject using the vesicles derived from bacteria of the genus Rhodococcus. The vesicles are significantly decreased in a clinical sample obtained from a patient with lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD, and dementia, compared with a normal individual, and administration of the vesicles to the patient inhibits the secretion of inflammation mediators caused by pathogenic vesicles such as E. coli-derived vesicles, and inhibits cranial nerve cell damage caused by stress hormones, therefore the vesicles are used in a method of diagnosing lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD, and/or dementia, and a method of alleviating or treating a malignant disease, diabetes, stroke, a cardiovascular disease, an inflammatory pulmonary disease, and/or a cranial nerve disease.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61Q 19/00 - Préparations pour les soins de la peau
Provided are vesicles derived from bacteria of the genus Weissella and a use thereof. The present inventors experimentally identified that vesicles derived from bacteria of the genus Weissella effectively suppress the secretion of inflammatory mediators from pathogenic vesicles inducing inflammation. Thus, it is expected that the vesicles derived from bacteria of the genus Weissella according to the presently claimed subject matter will be advantageously used for the purpose of developing a composition for preventing, alleviating, or treating inflammatory diseases.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
54.
COMPOSITION COMPRISING LACTOBACILLUS BACTERIUM-DERIVED VESICLE FOR PREVENTING OR TREATING METABOLIC DISEASE OR MUSCULAR DISEASE
The present invention relates to a composition comprising Lactobacillus bacterium-derived vesicles for preventing or treating a metabolic disease or a muscular disease. As the present inventors identified that when administered to animal models suffering from a high fat diet-induced metabolic disease, Lactobacillus bacterium-derived vesicles effectively repress the high fat diet-induced metabolic disease and activate the AMPK signaling in myocytes to increase homeostasis against metabolic stresses, the Lactobacillus bacterium-derived vesicles according to the present invention can be advantageously used for preventing a metabolic disease and a muscular disease such as obesity and the like, alleviating a symptom thereof, or treating the disease, or in developing a medicinal product or a health functional food for treating the disease.
The present invention relates to a composition which is for preventing, ameliorating, or treating neurological or psychiatric diseases, and comprises, as an active ingredient, vesicles derived from Lactobacillus paracasei. The present inventors found that when the vesicles derived from Lactobacillus paracasei were administered to a neurological disease transgenic animal model, brain-neural dysfunction was effectively inhibited, and also found that when the vesicles derived from Lactobacillus paracasei were administered to an animal model having a mental illness caused by mental stress, the occurrence of mental dysfunction caused by stress and behavioral disorders accompanying mental dysfunction were effectively inhibited. Vesicles derived from Lactobacillus paracasei according to the present invention can be effectively used in the development of pharmaceuticals or health functional foods for preventing or treating neurological or psychiatric diseases, or ameliorating symptoms thereof.
Provided are vesicles derived from bacteria of the genus Corynebacterium and a use thereof. The present inventors experimentally identified that vesicles derived from bacteria of the genus Corynebacterium were in reduced levels in clinical samples of patients with cirrhosis, stroke, diabetes, asthma, atopic dermatitis, depression, breast cancer, dementia, and nasal polyps, and effectively suppress the secretion of inflammatory mediators from pathogenic vesicles inducing inflammation. Thus, it is expected that the vesicles derived from bacteria of the genus Corynebacterium according to the presently claimed subject matter will be advantageously used as a composition for prevention or treatment of inflammatory diseases including cirrhosis, stroke, diabetes, asthma, atopic dermatitis, depression, breast cancer, dementia, nasal polyps, and the like.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
58.
COMPOSITION FOR REGULATING STEM CELL FUNCTION COMPRISING LACTOBACILLUS SP. BACTERIA-DERIVED EXTRACELLULAR VESICLES AS ACTIVE INGREDIENT
CHUNGBUK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (République de Corée)
Inventeur(s)
Kim, Yoon-Keun
Park, Yoon Shin
Choi, Da Hyeon
Abrégé
LactobacillusLactobacillus sp. bacteria-derived extracellular vesicles as an active ingredient, and a method for regulating a stem cell function using same. The Lactobacillus sp. bacteria-derived extracellular vesicles, according the present invention, have the effect of greatly improving the proliferation of stem cells, and the extracellular vesicles are naturally secreted from a Lactobacillus sp. strain symbiotic in human tonsillar tissue and are human-friendly and natural substances, and thus can be used in various research fields by promoting the proliferation of aged stem cells with minimal toxicity and side effects.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
Proteus, according to the present invention, may be usefully used for the development of a method of diagnosing cancer, cardiovascular diseases, metabolic diseases, neuropsychiatric diseases, allergic-respiratory diseases, and inflammatory bowel diseases, and a composition for prevention, treatment, and/or alleviation.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 38/00 - Préparations médicinales contenant des peptides
60.
METHOD FOR DIAGNOSIS OF STROKE THROUGH BACTERIAL METAGENOME ANALYSIS
The present invention relates to a method of diagnosing a stroke by bacterial metagenomic analysis, and more particularly, to a method of diagnosing a stroke by analyzing an increase or decrease in contents of specific bacteria-derived extracellular vesicles by performing bacterial metagenomic analysis using subject-derived samples. The extracellular vesicles secreted from bacteria present in the environment are absorbed into the body to have a direct influence on inflammation, and since a stroke is difficult to be diagnosed early before symptoms are shown, effective treatment is difficult. Therefore, by previously predicting the risk of the onset of a stroke through metagenomic analysis of bacterial extracellular vesicles using a human-derived sample according to the present invention, a stroke risk group may be diagnosed and predicted early to delay the time of onset or prevent the onset of a stroke with proper cure, and early diagnosis may be performed even after the onset of the disease, thereby reducing the incidence of a stroke and increasing a therapeutic effect.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
61.
Method for diagnosing cholangiocarcinoma via bacterial metagenomic analysis
The present invention relates to a method of diagnosing cholangiocarcinoma through bacterial metagenomic analysis, and more particularly to a method of diagnosing cholangiocarcinoma by analyzing an increase or decrease in content of specific bacteria-derived extracellular vesicles through bacterial metagenomic analysis using subject-derived samples. Extracellular vesicles secreted from bacteria present in the environment are absorbed into the body, and can directly affect the occurrence of cancer, and cholangiocarcinoma is difficult to diagnose early before symptoms appear so that effective treatment is difficult. Therefore, by previous diagnosis of the risk for the onset of cholangiocarcinoma through metagenomic analysis of bacterial extracellular vesicles using human-derived samples according to the present invention, the risk group of cholangiocarcinoma can be diagnosed and predicted early to delay or prevent the onset of cholangiocarcinoma through proper management, and early diagnosis can be performed even after the onset, thereby reducing the incidence of cholangiocarcinoma and increasing the therapeutic effect. In addition, the progression of cancer can be improved or the recurrence of cancer may be prevented by avoiding the exposure of causative factors through metagenomic analysis for patients diagnosed with cholangiocarcinoma.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
Faecalibacterium prausnitzii according to the subject matter are expected to be usefully employed for the purposes of developing a method for diagnosing gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and/or Parkinson's disease, and a composition for preventing, alleviating, or treating said diseases.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
63.
METHOD FOR DIAGNOSING COLORECTAL CANCER ON BASIS OF METAGENOME AND METABOLITE OF EXTRACELLULAR VESICLES
The present invention relates to a method for diagnosing colorectal cancer on the basis of a metagenome and metabolites of extracellular vesicles. The method for diagnosing colorectal cancer according to the present invention may diagnose and predict colorectal cancer early through metagenomic analysis of extracellular vesicles secreted by intestinal bacteria and analysis of metabolites in the extracellular vesicles may confirm the presence of extracellular vesicles derived from bacteria with significantly changed content from colorectal cancer and metabolites such as amino acids, amino alcohols, aromatic alcohols, carboxylic acids, and fatty acids, and may confirm association of the extracellular vesicles and the metabolites to use together as biomarkers, thereby improving the accuracy of colorectal cancer diagnosis, lower the incidence of colorectal cancer, and increase therapeutic effects.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
64.
LUNG DISEASE DIAGNOSTIC METHOD BASED ON ANTIBODIES AGAINST MICROORGANISM-DERIVED VESICLES
The present invention relates to lung disease diagnostic methods based on antibodies against microorganism-derived vesicles and, more particularly, to a method for diagnosing lung diseases by performing bacterial metagenome analysis using samples derived from a subject to analyze an increase or decrease in IgG, IgG1 and/or IgG4 levels in extracellular vesicles derived from specific bacteria.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Lactococcus can be effectively used for a method of diagnosing diabetes, myocardial infarction, atrial fibrillation, stroke, renal failure, Parkinson's disease or depression, and a composition for preventing or treating the disease or inflammatory disease.
Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease, and a composition for preventing or treating the diseases or an inflammatory disease.
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
Provided are vesicles derived from bacteria of the genus Lactobacillus and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in samples obtained from patients with stomach cancer, renal failure, dementia and stroke, compared with a normal individual, and the vesicles inhibited the secretion of inflammatory mediators caused by pathogenic vesicles, was significantly inhibited. Therefore, it is expected that the vesicles derived from bacteria of the genus Lactobacillus according to the present invention can be effectively used for a method of diagnosing stomach cancer, renal failure, dementia or stroke, and for developing a composition for preventing, alleviating or treating an inflammatory disease accompanied by immune dysfunction, including the diseases.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
68.
Nanovesicles derived from enhydrobacter bacteria, and use thereof
Enhydrobacter bacteria according to the present invention can be effectively used for a method of diagnosing pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, lymphoma, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, liver cirrhosis, or diabetes, and for developing a composition for preventing, alleviating or treating the diseases.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
Cupriavidus may be usefully used for the purpose of developing a method of diagnosing a malignant diseases such as gastric cancer, colon cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, prostate cancer, head and neck cancer, lymphoma, and the like, heart diseases such as cardiomyopathy, atrial fibrillation, variant angina, and the like, chronic obstructive pulmonary disease, stroke, diabetes, kidney failure, dementia, Parkinson's disease, or depression, and a composition for preventing or treating the diseases.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
70.
METHOD FOR DIAGNOSING BRAIN TUMOR THROUGH BACTERIAL METAGENOMIC ANALYSIS
SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (République de Corée)
Inventeur(s)
Kim, Yoon-Keun
Paek, Sun Ha
Moon, Hyo Eun
Park, Hyung Woo
Abrégé
The present invention relates to a method for diagnosing a brain tumor through bacterial metagenomic analysis and, more specifically, to a method for diagnosing a brain tumor by performing bacterial metagenomic analysis using samples of normal individuals and subjects and analyzing an increase or decrease in the content of extracellular vesicles derived from specific bacteria. By pre-diagnosing the risk of developing a brain tumor through metagenomic analysis of bacteria-derived extracellular vesicles using human-derived samples according to the present invention, early diagnosis and prediction is possible for risk groups of autism, and also the onset time can be delayed or the onset can be prevented through appropriate management. In addition, there are the advantages that early diagnosis can be performed even after the onset, such that the incidence of brain tumors can be lowered and therapeutic effects can be increased, as well as in patients diagnosed with brain tumors, by avoiding exposure to causative factors through metagenomic analysis, the course of the disease can be improved and recurrence can be prevented.
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (République de Corée)
GIL MEDICAL CENTER (République de Corée)
Inventeur(s)
Kim, Yoon-Keun
Lee, Dae Ho
Abrégé
The present invention relates to a method for predicting or diagnosing progressive diabetic nephropathy through the analysis of microRNA contained in urine-derived vesicles and, more particularly, to a method for predicting or diagnosing the risk of developing progressive diabetic nephropathy by analyzing an increase or decrease in the expression level of specific microRNA through microRNA analysis in urine-derived vesicles.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
72.
NANOVESICLES DERIVED FROM RHIZOBIUM SP. BACTERIA, AND USE THEREOF
The present invention relates to vesicles derived from bacteria of the genus Rhizobium and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in clinical samples obtained from patients with stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, Parkinson's disease and dementia, compared with a normal individual, and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited. Therefore, it is expected that the vesicles derived from bacteria of the genus Rhizobium according to the present invention can be effectively used for a method of diagnosing stomach cancer, colon cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, asthma, diabetes, Parkinson's disease or dementia, and for developing a composition for preventing, alleviating or treating the diseases.
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
73.
NANOVESICLES DERIVED FROM BLAUTIA BACTERIA AND USE THEREOF
Provided are vesicles derived from bacteria of the genus Blautia and a use thereof for diagnosing colon cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation or variant angina pectoris, and for developing a composition for preventing, alleviating or treating a colorectal disease, a liver disease, a pancreatic disease, cholangiocarcinoma, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation, variant angina pectoris or a graft-versus-host disease.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
Streptococcus pyogenes culture broth or the protein isolated from the culture broth according to the presently claimed subject matter can be effectively used to develop a drug, a health functional food, an inhalant, a cosmetic composition, or the like for preventing inflammatory diseases, metabolic diseases, and cancer, or alleviating or treating symptoms thereof.
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
75.
METHOD FOR DIAGNOSING GASTRIC CANCER THROUGH QPCR ANALYSIS
The present invention relates to a method for diagnosing gastric cancer through qPCR analysis, which is a method for diagnosing gastric cancer by measuring the amount of microorganisms contained in a fecal sample to be analyzed. The diagnostic method, according to the present invention, can predict and/or diagnose gastric cancer with high accuracy and sensitivity by using feces that can be easily obtained without pain from a subject to be diagnosed, and thus can be widely used in the field of gastric cancer diagnosis as well as enable early diagnosis of gastric cancer, so that it is expected that the effectiveness of gastric cancer treatment can be remarkably increased.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
76.
METHOD FOR DIAGNOSIS OF COLITIS THROUGH QPCR ANALYSIS
The present invention relates to a method for diagnosis of colitis through qPCR analysis and to a method for diagnosis of colitis by measuring levels of microorganisms in fecal samples to be analyzed. The diagnosis method according to the present invention can predict and/or diagnose colitis at high accuracy and sensitivity by using feces, which can be easily acquired without pain from a subject to be diagnosed, and as such, can find a wide range of applications in the colitis diagnosis field and, as a result, is expected to enable early diagnosis of colitis, thereby remarkably increasing the effects of colitis cancer treatment.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
77.
STREPTOCOCCUS PYOGENES BACTERIA-DERIVED PROTEIN, AND USE THEREOF
Streptococcus pyogenesStreptococcus pyogenesStreptococcus pyogenes culture or a protein isolated from the culture had anti-inflammatory, anti-obesity, liver function-improving, and anti-cancer effects on inflammatory disease, metabolic disease, and cancer models. Thus, a Streptococcus pyogenes culture or a protein isolated from the culture according to the present invention can be advantageously used in the development of medicines or health functional foods, inhalants, cosmetics, etc. for preventing or treating inflammatory disease, metabolic disease, and cancer, or ameliorating the symptoms thereof.
A61K 35/744 - Bactéries lactiques, p. ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
78.
Method for diagnosing lymphoma via bacterial metagenomic analysis
Provided is a method of diagnosing lymphoma by analyzing an increase or decrease in contents of specific bacterial extracellular vesicles by performing bacterial metagenomic analysis using normal individual and subject-derived samples, wherein a lymphoma risk group may be diagnosed and predicted early to delay the time of onset or prevent the onset of lymphoma with proper cure, and after onset, early diagnosis may be performed, thereby reducing the incidence of lymphoma and increasing a therapeutic effect.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
79.
NANOVESICLES DERIVED FROM BACTERIA OF GENUS ROTHIA, AND USE THEREOF
The present invention relates to vesicles derived from bacteria of genus Rothia, and a use thereof. The present inventors experimentally ascertained that the vesicles in clinical samples of patients with diabetes, atrial fibrillation, cardiomyopathy, liver cancer, cirrhosis, dementia, depression, Parkinson's disease, and atopic dermatitis are significantly reduced compared to those of normal people, the secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles is significantly inhibited when the vesicles separated from the strain are administered, and vesicles derived from bacteria of the genus Rothia significantly inhibit cranial nerve cell damage caused by stress hormones, and thus vesicles derived from bacteria of the genus Rothia, according to the present invention, are expected to be effectively usable for the purpose of developing a method for diagnosing diabetes, atrial fibrillation, cardiomyopathy, liver cancer, cirrhosis, dementia, depression, Parkinson's disease, and atopic dermatitis, and a composition for preventing or treating diabetes, cardiovascular diseases, liver diseases, cranial nerve diseases, and inflammatory diseases.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
80.
NANOVESICLES DERIVED FROM BACTERIA OF GENUS DEINOCOCCUS, AND USE THEREOF
The present invention relates to vesicles derived from bacteria of the genus Deinococcus, and a use thereof. The present inventors experimentally ascertained that the vesicles in clinical samples of cancer, inflammatory disease and dementia patients are significantly more reduced than those in normal people, the secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles is significantly inhibited when the vesicles isolated from the strain are administered, and vesicles derived from bacteria of the genus Deinococcus significantly inhibit cranial nerve cell damage caused by stress hormones, and thus it is expected that vesicles derived from bacteria of the genus Deinococcus, according to the present invention, can be effectively used for the purpose of developing a method for diagnosing cancer, inflammatory diseases and/or dementia and a composition for preventing, alleviating or treating cancer, inflammatory diseases and/or cranial nerve diseases.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
The resent invention relates to nanovesicles derived from bacteria of genus Rhodococcus, and a use thereof. The present inventors experimentally ascertained that vesicles in clinical samples of patients with lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD and dementia are significantly reduced compared to those of normal people, the secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles is significantly inhibited when the vesicles separated from the strain are administered, and vesicles derived from bacteria of the genus Rhodococcus significantly inhibit cranial nerve cell damage caused by stress hormones, and thus vesicles derived from bacteria of the genus Rhodococcus, according to the present invention, are expected to be effectively usable for the purpose of developing a method for diagnosing lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD and/or dementia, and a composition for preventing or treating malignant disease, diabetes, stroke, cardiovascular disease, inflammatory lung disease, and/or cranial nerve diseases.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
The present invention relates to vesicles derived from Lactobacillus paracasei, and a use of same, and more specifically, to a composition for alleviating, preventing, and treating inflammatory diseases and cancer, comprising, as an effective component, vesicles derived from Lactobacillus paracasei capable of effectively inhibiting various inflammatory responses.
A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61Q 19/00 - Préparations pour les soins de la peau
A61K 35/742 - Bactéries sporulées, p. ex. Bacillus coagulans, Bacillus subtilis, clostridium ou Lactobacillus sporogenes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION (République de Corée)
Inventeur(s)
Kim, Yoon-Keun
Ban, Changill
Abrégé
The present invention relates to a DNA aptamer binding specifically to Dengue virus envelope protein domain III (DENV EDIII), a composition comprising same for diagnosing Dengue fever, and a kit for diagnosis of Dengue fever. Intensive and thorough research, conducted by the present inventors, into the development of a novel biomarker for diagnosis of Dengue fever resulted in the finding that a DNA aptamer able to bind specifically to Dengue virus envelope protein domain III (DENV EDIII) has strong binding affinity and excellent specificity for DENV EDIII. The DNA aptamer is expected to be higher in stability than conventional ELISA methods utilizing antibodies and as such, can be advantageously used in developing a composition for diagnosis of Dengue fever and a kit for diagnosis of Dengue fever.
C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
86.
DNA APTAMER SPECIFICALLY BINDING TO YELLOW FEVER VIRUS EDIII, AND USE THEREOF
POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION (République de Corée)
Inventeur(s)
Kim, Yoon-Keun
Ban, Changill
Abrégé
The present invention relates to a DNA aptamer specifically binding to yellow fever virus envelope protein domain III (YFV EDIII), a composition for diagnosing yellow fever, containing same, a kit for diagnosing yellow fever, a biosensor for diagnosing yellow fever, and an information providing method for diagnosing yellow fever. As a result of a formal study performed by the present inventors in order to develop a novel biomarker for the diagnosis of yellow fever, it has been confirmed that a DNA aptamer having specific binding ability to YFV EDIII has strong binding force and excellent specificity with YFV EDIII. Therefore, the present invention is expected to have greater stability than an ELISA method using existing antibodies, and thus is expected to be effectively usable in the development of a composition for diagnosing yellow fever, a biosensor for diagnosing yellow fever, and an information providing method for diagnosing yellow fever and the like.
C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
G01N 27/02 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance
G01N 27/26 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant des variables électrochimiquesRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en utilisant l'électrolyse ou l'électrophorèse
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
87.
DNA APTAMER BINDING SPECIFICALLY TO CHIKUNGUNYA VIRUS E2 AND USE THEREOF
POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION (République de Corée)
Inventeur(s)
Kim, Yoon-Keun
Ban, Changill
Abrégé
The present invention relates to a DNA aptamer binding specifically to Chikungunya virus envelope protein 2 (CHIKV E2), a composition comprising same for diagnosing chikungunya, a kit for diagnosis of chikungunya, a biosensor for diagnosis of chikungunya, and a method for providing information for diagnosis of chikungunya. Intensive and thorough research, conducted by the present inventors, into the development of a novel biomarker for diagnosis of chikungunya resulted in the finding that a DNA aptamer able to bind specifically to Chikungunya virus envelope protein 2 (CHIKV E2) has strong binding affinity and excellent specificity for CHIKV E2. The DNA aptamer is expected to be higher in stability than conventional ELISA methods utilizing antibodies and as such, can be advantageously used in developing a composition for diagnosis of chikungunya, a biosensor for diagnosis of chikungunya, and a method for providing information for diagnosis of chikungunya.
C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
G01N 27/02 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance
G01N 27/26 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant des variables électrochimiquesRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en utilisant l'électrolyse ou l'électrophorèse
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
88.
NANOVESICLES DERIVED FROM BACTERIA OF GENUS SPHINGOMONAS AND USES OF SAME
The present invention relates to vesicles derived from bacteria of the genus Sphingomonas, and uses of same. The present inventors confirmed through experiments that compared to a normal individual, there is a significant decrease of said vesicles in clinical samples of patients with cirrhosis, liver cancer, myocardial infarction, kidney failure, diabetes, brain tumor, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, and that an administration of vesicles isolated from the strains significantly suppresses the secretion of inflammatory mediators by pathogenic vesicles, such as vesicles derived from E. coli, wherein said vesicles, when orally administered, are distributed to brain tissues. Accordingly, the vesicles derived from bacteria of the genus Sphingomonas according to the present invention have promising uses in: developing detection methods for cirrhosis, liver cancer, myocardial infarction, kidney failure, diabetes, brain tumor, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis; compositions for preventing, alleviating or treating said diseases; and drug carriers enabling the delivery of drugs to the brain.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
The present invention pertains to a Weissella bacteria-derived vesicle and a use thereof. The present inventors have experimentally confirmed that Weissella bacteria-derived vesicles efficiently inhibit inflammatory mediator secretion due to inflammation-inducing pathogenic vesicles, and it is thus expected that a Weissella bacteria-derived vesicle according to the present invention will be able to be usefully used for the purpose of developing a composition for preventing, alleviating, or treating inflammatory diseases.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61Q 19/00 - Préparations pour les soins de la peau
90.
NANO-VESICLE DERIVED FROM CORYNEBACTERIUM SP. BACTERIA AND USE THEREOF
The present invention relates to vesicles derived from Corynebacterium sp. bacteria and a use thereof. The present inventors experimentally identified that vesicles derived from Corynebacterium sp. bacteria were in reduced levels in clinical samples of patients with liver cirrhosis, stroke, diabetes, asthma, atopic dermatitis, depression, breast cancer, dementia, or nasal polyps and effectively suppress the secretion of inflammatory mediators from pathogenic vesicles inducing inflammation. Thus, it is expected that the vesicles derived from Corynebacterium sp. bacteria according to the present invention will be advantageously used as a composition for prevention or treatment of inflammatory diseases including cirrhosis, stroke, diabetes, asthma, atopic dermatitis, depression, breast cancer, dementia, and nasal polyps.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61Q 19/00 - Préparations pour les soins de la peau
91.
METHOD OF DIAGNOSING HEART DISEASE THROUGH BACTERIAL METAGENOME ANALYSIS
The present invention relates to a method of diagnosing heart disease through bacterial metagenome analysis. More specifically, the present invention relates to a method of predicting the causative factor and onset of heart disease, diagnosing heart disease early, and predicting prognosis by analyzing the increase or decrease in the content of an extracellular vesicle derived from specific bacteria by performing bacterial metagenome analysis using a subject-derived sample. Through metagenome analysis of a bacteria-derived extracellular vesicle using a human body-derived sample according to the present invention, the risk of the onset of heart disease is predicted in advance, and thus a risk group for heart disease is diagnosed and predicted early. Accordingly, through suitable management, the moment of onset of disease can be performed even after the onset of disease. Therefore, the rate of onset of heart disease can be reduced, and the effect of treatment can be improved. In addition, since exposure to causative factors is avoided through metagenome analysis in a patient diagnosed with heart disease, the prognosis of heart disease can be improved, or reoccurrence of heart disease can be prevented.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
92.
INFLAMMATORY BOWEL DISEASE DIAGNOSTIC METHOD BY MEANS OF BACTERIAL METAGENOMIC ANALYSIS
The present invention relates to a method for prognosing the occurrence and the causative factor of an inflammatory bowel disease such as ulcerative colitis and Crohn's disease by means of a metagenomic analysis of bacteria and bacteria-derived vesicles present in a human body-derived substance and, more particularly, to a method for diagnosing the causative factor and occurrence risk of an inflammatory bowel disease by analyzing a metagenomic sequence present in bacteria and bacteria-derived vesicles present in stool. Trillions of bacteria are present in the intestine, and vesicles are secreted outside the cells for exchange of information. Bacteria are not absorbed into the intestinal epithelial cells, but the vesicles secreted from the bacteria pass through the mucous, are absorbed into the intestinal epithelial cells and can increase or reduce inflammation. The present invention can be facilitated as a method for diagnosing the occurrence risk and causative factor of an inflammatory bowel disease by means of a gene metagenomic sequence analysis of bacteria and bacteria-derived vesicles present in a human body-derived substance. Also, the present invention enables early diagnosis even after an occurrence of an inflammatory bowel disease, reduces the occurrence of an inflammatory bowel disease, and can enhance therapeutic effects.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
Micrococcus, a composition and a use thereof, wherein the vesicles and the composition comprising the same may be effectively used for the development of a method of diagnosing gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, chronic obstructive pulmonary disease (COPD), dementia, or diabetes.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
94.
METHOD FOR DIAGNOSING COLON CANCER THROUGH QPCR ANALYSIS
The present invention relates to a method for diagnosing colon cancer through qPCR analysis, and to a method for diagnosing colon cancer by measuring the number of microbes contained in a fecal sample to be analyzed. The diagnostic method according to the present invention enables colon cancer to be predicted or diagnosed with high accuracy and sensitivity by using feces that can be easily obtained, without pain, from a subject to be diagnosed, and thus is widely usable in the field of colon cancer diagnosis and, as a result, is expected to enable early diagnosis of colon cancer, thereby remarkably increasing the effects of colon cancer treatment.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
Propionibacterium according to the present invention are expected to be advantageously used in a method for diagnosis or prediction of cancers, inflammatory diseases, endocrine diseases, or metabolic diseases, a pharmaceutical composition, a food, a cosmetic product, and the like.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
LactobacillusLactobacillusLactobacillus sp. bacteria, according to the present invention, may be usefully employed for the purpose of developing: a method for diagnosing stomach cancer, renal failure, dementia or stroke; and a composition for preventing, improving or treating inflammatory diseases, including said diseases, accompanied by immune dysfunction.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
EnhydrobacterEnhydrobacterEnhydrobacter bacteria, according to the present invention, may be usefully employed for the purpose of developing: a method for diagnosing pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, lymphoma, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, cirrhosis or diabetes; and a composition for preventing, improving or treating said diseases.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
CollinsellaCollinsellaCollinsella sp. bacteria, according to the present invention, may be usefully employed for the purpose of developing: a method for diagnosing stomach cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, myocardial infarction, atrial fibrillation, COPD, diabetes, mild cognitive impairment and Alzheimer's dementia; and a composition for preventing, treating or improving said diseases or inflammatory diseases accompanied by immune dysfunction.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
MethylobacteriumMethylobacteriumMethylobacterium sp. bacteria, according to the present invention, may be usefully employed for the purpose of developing: a method for diagnosing pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, cardiomyopathy, variant angina, diabetes or Parkinson's disease; and a composition for preventing, improving or treating said diseases.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
CoprococcusCoprococcusCoprococcus sp. bacteria, according to the present invention, may be usefully employed for the purpose of developing: a method for diagnosing breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy or atrial fibrillation; and a composition for preventing, treating or improving gastritis, stomach cancer, colitis, colorectal cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation or inflammatory diseases.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
brevets
